Release of a novel peptide from ferritin nanocages: A new tool for therapeutic applications

Biochim Biophys Acta Gen Subj. 2024 Feb;1868(2):130525. doi: 10.1016/j.bbagen.2023.130525. Epub 2023 Dec 2.

Abstract

The development of new drug delivery systems for targeted chemotherapy release in cancer cells represents a very promising tool. In this contest, protein-based nanocages have considerable potential as drug delivery devices. Notably, ferritin has emerged as an excellent candidate due to its unique architecture, surface properties and high biocompatibility. A promising strategy might then involve ferritin cargos for specifical release of AntiMicrobial Peptides endowed with anticancer activity to cancer cells. In this paper, we encapsulated the TRIL analogue of Temporin-L peptide within a ferritin nanocage and evaluated the cargo biological properties. The results demonstrated a reduced haemolytic activity of the peptide and a selective cytotoxicity activity on cancer cells likely mediated by oxidative stress while having no effects on non-tumoral cells. The combination of the properties of ferritin with TRIL, might open up the way to the development of novel peptide delivery systems for future pharmaceutical applications.

Keywords: Anticancer activity; Drug delivery; Ferritin nanocage; ROS production; TRIL.

MeSH terms

  • Drug Delivery Systems / methods
  • Ferritins* / chemistry
  • Peptides* / chemistry
  • Peptides* / pharmacology

Substances

  • Ferritins
  • Peptides